Table 3.
Comparison of Endophthalmitis Rates Before and After Universal Masking by Medication Type.
| Medication | Pre-universal Masking | Universal Masking | ||||||
|---|---|---|---|---|---|---|---|---|
| Infections | Total Injections | Infection Rate, % (per No. of Injections) |
Infections | Total Injections | Infection Rate, % (per No. of Injections) |
Relative risk (95% CI) |
P Value | |
| Ranibizumab combined a | 22 | 104 650 | 0.021 (1 of 4762) |
8 | 42 949 | 0.019 (1 in 5263) |
0.886 (0.395-1.990) |
.84 |
| Bevacizumab | 9 | 43 367 | 0.021 (1 of 4762) |
6 | 13 502 | 0.044 (1 in 2273) |
2.141 (0.762-6.015) |
.14 |
| Aflibercept | 38 | 67 428 | 0.056 (1 of 1786) |
10 | 30 547 | 0.033 (1 in 3030) |
0.581 (0.290-1.166) |
.16 |
| Dexamethasone implant | 2 | 2303 | 0.087 (1 of 1149) |
4 | 880 | 0.455 (1 in 220) |
5.234 (0.960-28.526) |
.05 |
| Triamcinolone acetonide | 2 | 1383 | 0.145 (1 of 690) |
0 | 340 | — | — | — |
| Total | 73 | 219 131 | 0.033 (1 of 3030) |
28 | 88 218 | 0.032 (1 in 3150) |
0.953 (0.616-1.473) |
.91 |
a
Includes doses 0.5 mg/0.05 mL and 0.3 mg/0.05 mL.